Pyxis Oncology (PYXS) Enterprise Value (2020 - 2025)
Pyxis Oncology's (PYXS) quarterly Enterprise Value came in at -$66.9 million in Q4 2025, up 47.33% year-on-year from -$45.4 million in Q4 2024, and up 12.33% on a QoQ basis from -$76.3 million in Q3 2025.
Pyxis Oncology (PYXS) Enterprise Value (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Enterprise Value data on file, last reported at -$66.9 million in Q4 2025.
- On a quarterly basis, Enterprise Value rose 47.33% year-over-year to -$66.9 million in Q4 2025; TTM through Dec 2025 was -$66.9 million, a 47.33% increase from a year earlier, with the FY2025 full-year figure at -$66.9 million, up 47.33% from the prior year.
- Enterprise Value for Q4 2025 stood at -$66.9 million, up from -$76.3 million in the prior quarter.
- Over the last five years, Enterprise Value for PYXS reached as high as -$12.2 million in Q2 2025 and fell as low as -$276.2 million in Q4 2021.
- Historically, Enterprise Value has averaged -$118.9 million across 5 years, with a median of -$129.9 million in 2023.
- Across the five-year window, Enterprise Value slumped 1086.88% in 2021 and soared 87.83% in 2023, its largest moves.
- Year by year, Enterprise Value stood at -$276.2 million in 2021, then surged by 34.55% to -$180.8 million in 2022, then soared by 34.0% to -$119.3 million in 2023, then decreased by 6.4% to -$126.9 million in 2024, then surged by 47.33% to -$66.9 million in 2025.
- Per Business Quant data, the three most recent Enterprise Value figures were -$66.9 million in Q4 2025, -$76.3 million in Q3 2025, and -$12.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn | -66.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -66.86 Mn |
| Sep 30, 2025 | -76.26 Mn |
| Jun 30, 2025 | -12.21 Mn |
| Mar 31, 2025 | -14.23 Mn |
| Dec 31, 2024 | -126.93 Mn |
| Sep 30, 2024 | -144.82 Mn |
| Jun 30, 2024 | -26.55 Mn |
| Mar 31, 2024 | -29.44 Mn |
| Dec 31, 2023 | -119.30 Mn |
| Sep 30, 2023 | -132.97 Mn |
| Jun 30, 2023 | -27.37 Mn |
| Mar 31, 2023 | -54.53 Mn |
| Dec 31, 2022 | -180.77 Mn |
| Sep 30, 2022 | -200.01 Mn |
| Jun 30, 2022 | -224.83 Mn |
| Mar 31, 2022 | -248.56 Mn |
| Dec 31, 2021 | -276.21 Mn |
| Sep 30, 2021 | -133.48 Mn |
| Jun 30, 2021 | -142.47 Mn |
| Mar 31, 2021 | -140.66 Mn |